NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01802749,Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer,https://clinicaltrials.gov/study/NCT01802749,MITO16MANGO2b,UNKNOWN,"Bevacizumab has been found to prolong progression free survival in first line, and more recently, in second line treatment for platinum sensitive ovarian cancer patients who had not received prior treatment with bevacizumab.

Recently reported data suggest that patients with colon cancer who receive bevacizumab in more than one line of therapy (beyond progression) have better results. In ovarian cancer, the role of bevacizumab administered in both first and second-line therapies needs to be defined.

This study aims to evaluate whether administering bevacizumab in combination with chemotherapy in second-line therapy to patients with recurrent ovarian cancer who have received first-line bevacizumab will be more effective than chemotherapy alone.",NO,Recurrent Ovarian Cancer,DRUG: Bevacizumab|DRUG: Paclitaxel|DRUG: Carboplatin|DRUG: pegylated liposomal doxorubicin|DRUG: Gemcitabine,"progression free survival, assessed by local Investigator, 12 months","overall survival, 12 months|number of complete or partial responses, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, 6 months|worst grade toxicity per patient, according to Common Toxicity Criteria for Adverse Events v. 4.03, evaluated every 3 weeks up to 12 months|number of patients taking oral antidiabetic therapy, at baseline|number of patients taking antithrombotic therapy, at baseline|progression free survival, as measured by independent central review, 12 months","predictive clinical factors for efficacy of bevacizumab, 12 months|correlation of baseline plasma biomarker expression and clinical outcome, 12 months","National Cancer Institute, Naples",Mario Negri Institute for Pharmacological Research,FEMALE,"ADULT, OLDER_ADULT",PHASE3,406,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,MITO-16 -MANGO-OV2b|2012-004362-17|ENGOT-ov 17,2013-11,2023-12,2023-12,2013-03-01,,2023-03-24,"Centre Hospitalier d'Aix-en-Provence, Aix-en-Provence, France|Hôpital de la Côte Basque, Bayonne, France|Institut Bergoniè, Bordeaux, France|Hôpital Fleyriat, Bourg-en-Bresse, France|Centre François Baclesse, Caen, France|Centre Hospitalier Intercommunal de Créteil, Créteil, France|Centre d'Oncologie et de Radiothérapie, Dijon, France|Centre Georges Francois Leclerc, Dijon, France|Centre Hospitalier du Mans, Le Mans, France|Centre Hospitalier Universitaire Dupuytren, Limoges, France|Centre Léon Bérard, Lyon, France|Clinique de la Sauvegarde, Lyon, France|Hôpital Nord, Marseille, France|Hôpital Saint-Joseph, Marseille, France|Clinique Claude Bernard, Metz, France|Centre Azuréen de Cancérologie, Mougins, France|Centre Hospitalier Général de Pau, Paris, France|Hopital Cochin, Paris, France|Hôpital des Diaconesses, Paris, France|Hôpital Tenon, Paris, France|Centre Hospitalier Général de Pau, Pau, France|Centre Hospitalier de la Région d'Annecy, Pringy, France|Institut Jean Godinot, Reims, France|Hopital Renè Huguenin, Institut Curie, Saint Cloud, France|Hôpital Inter Armées de Begin (HIA Begin),, Saint Mande, France|GHPSO, Senlis, France|Centre de Radiothèrapie - Clinique Sainte-Anne, Strasbourg, France|Clinique des Dentellières,, Valenciennes, France|Institut de Cancérologie Gustave Roussy, Villejuif, France|Anticancer Hospital Agio Savvas, Athens, Greece|General Hospital of Athens Alexandra, Athens, Greece|General Oncology Hospital Agii Anargiri, Athens, Greece|General Hospital of Thessaloniki Papageorgiou, Thessaloniki, Greece|Centro di Riferimento Oncologico, Aviano, Italy|A.O. G. Rummo, Benevento, Italy|Spedali Civili Università di Brescia, Brescia, Italy|Ospedale Senatore Antonio Perrino, Brindisi, Italy|Fondazione del Piemonte per l'Oncologia IRCCS, Candiolo, Italy|Osp. Cannizzaro, Catania, Italy|Ospedale Civile di Faenza, Faenza, Italy|I.R.C.C.S. San Martino IST, Genova, Italy|Ospedale Galliera, Genova, Italy|ASL 5 Spezzino Ospedale Felettino, La Spezia, Italy|A.O. Vito Fazzi, Lecce, Italy|Ospedale Manzoni di Lecco, Lecco, Italy|Istituto Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy|Istituto Europeo di Oncologia, Milano, Italy|Istituto Nazionale Tumori, Milano, Italy|U.L.S.S. 13, Mirano, Italy|A.O.U. Federico II, Napoli, Italy|A.O.U. Seconda Università di Napoli, Napoli, Italy|Istituto Nazionale dei Tumori , Oncologia Medica - Dipartimento Uro-Ginecologico, Napoli, Italy|Ist. Sacro Cuore Don Calabria, Negrar, Italy|NO AOU Maggiore della Carità, Novara, Italy|Istituto Oncologico Veneto, Padova, Italy|Casa di Cura La Maddalena, Palermo, Italy|Osp Silvestrini, Perugia, Italy|Ospedale Santa Chiara, Pisa, Italy|A.O. S. Maria degli Angeli, Pordenone, Italy|AO ASL 4, Prato, Italy|Ospedale S. Maria delle Croci AUSL di Ravenna, Ravenna, Italy|Arcispedale S. Maria Nuova, Reggio Emilia, Italy|Ospedale Civile Rimini, Rimini, Italy|Ospedale S. Giovanni Calibita Fatebenefratelli, Roma, Italy|Policlinico Universitario Gemelli Università Cattolica del Sacro Cuore, Roma, Italy|Policlinico Università Campus Biomedico, Roma, Italy|Ospedale di Sondrio, Sondrio, Italy|A.O. Ordine Mauriziano, Torino, Italy|A.O. di Udine S. Maria della Misericordia, Udine, Italy|Centre Hospitalier Princesse Grace, Monaco, Monaco|Zentrum fùr Onkologie/ Hamat. und Transf, Aarau, Switzerland|Universitatsspital,Frauenklinik, Basel, Switzerland|IOSI, Bellinzona, Switzerland|Klinik Engeried, Bern, Switzerland|Kantonsspital, Chur, Switzerland|Kantonsspital, Frauenfeld, Switzerland|HUG Breast Center, Geneva, Switzerland|Kantonsspital, Luzern, Switzerland|Kantonsspital, Munsterlingen, Switzerland|Kantonsspital, Olten, Switzerland|Klinische Forschung Onkologie, St. Gallen, Switzerland|Kantonsspital, Winterthur, Switzerland",
